Press Releases for VRTX

Press Releases
The Fortune Financial Undertakes Review of Stocks in the Healthcare and Services Sectors
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Adams Global Growth Conference
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Vertex Pharmaceuticals Reports Second Quarter 2009 Financial Results and Highlights Recent Clinical Progress and Business Development Activity
Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation Amend Agreement to Develop and Commercialize Telaprevir in Asia
Vertex Pharmaceuticals Announces the Date of its Second Quarter 2009 Financial Results Conference Call and Webcast
Third Rock Ventures Expands Team With Biotech Veterans
BenchmarkJournal.Com Free Analyst Review for SWHC, AMAT, SYNA, VRTX, CPHD and AKAM
Vertex Pharmaceuticals Announces Intention to Sell Its Rights to European Milestone Payments for Telaprevir
Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals’ Board of Directors
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2009 Piper Jaffray Europe Conference
Vertex Pharmaceuticals Announces Agreements to Exchange an Additional $40.2 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock
Vertex Pharmaceuticals Announces Agreements to Exchange $103.3 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Vertex Pharmaceuticals Initiates Phase 3 Registration Program for VX-770, an Oral CFTR Potentiator Targeting the Defective Protein Responsible for Cystic Fibrosis
New Report Forecasts Hepatitis C Virus Epidemic Among Baby Boomers; Untreated HCV Progressing to Severe Liver Disease Seen Driving U.S. Costs to $85 Billion
Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences
Vertex Promotes Dr. Peter Mueller to Global R&D Chief and Chief Science Officer
BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results
New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir
Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study
Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir’s Potential for Use in a Broad Range of HCV Patients and Highlighting the Company’s Expanded STAT-C Portfolio
Vertex Pharmaceuticals Reviews First Quarter Business Progress and Reports First Quarter 2009 Financial Results
Vertex Pharmaceuticals Announces the Date of its First Quarter 2009 Financial Results Conference Call and Webcast
TheFortuneFinancial.Com Initializes Free Analyst Research on VPHM, DNDN, BEAV and VRTX
Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR Corrector VX-809 in Patients with Cystic Fibrosis
CORRECTING and REPLACING Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VCH-222 Abstracts for Presentation at EASL Annual Meeting
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VCH-222 Abstracts for Presentation at EASL Annual Meeting
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Cowen & Company 29th Annual Health Care Conference
Vertex Pharmaceuticals Closes on Acquisition of ViroChem Pharma
Vertex Pharmaceuticals Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir
Vertex Pharmaceuticals Announces Pricing of Common Stock Offering
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock - Feb 18 2009 4:21PM
Zacks Analyst Blog Highlights: Intel, Vertex Pharmaceuticals, Schering-Plough, Vocus and Sohu.Com, Inc.
Vertex Pharmaceuticals Provides HCV and Cystic Fibrosis Update and Reports 2008 Financial Results
BenchmarkJournal.Com (Complimentary) Analyst Review for UNCL, DPTR, CPST and VRTX
Vertex Pharmaceuticals Announces Transition in Company Leadership
Vertex Pharmaceuticals Announces the Date of its 2008 Financial Results Conference Call and Webcast
Vertex Outlines 2009 Business Priorities: Registration Programs in Hepatitis C and Cystic Fibrosis; Balanced Investment to Maintain Financial Strength
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 27th Annual J.P. Morgan Healthcare Conference
Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences - Nov 26 2008 9:39AM
Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences - Nov 14 2008 9:31AM
Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences - Nov 6 2008 5:02PM
New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection
Zacks Analyst Blog Highlights: Cache, Inc., WPP Group Plc., Companhia Vale Do Rio Doce, Vertex Pharmaceuticals Inc. And Johnson & Johnson
Vertex Pharmaceuticals Highlights Progress with Hepatitis C and Cystic Fibrosis Programs and Reports Third Quarter 2008 Results
Vertex Announces Positive 28-Day Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis
Vertex Pharmaceuticals Announces the Date of its Third Quarter 2008 Financial Results Conference Call and Webcast
Vertex Pharmaceuticals Announces Webcast of its Presentation at the JMP Securities Healthcare Focus Conference
Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatology
Telaprevir Presentations at the 59th AASLD Meeting to Feature SVR Data in Treatment-Naive and Treatment-Failure Genotype 1 HCV Patients, and Clinical Data Exploring Twice-Daily Dosing Regimens
Vertex Pharmaceuticals Announces Exercise of Option to Purchase Additional Shares
Vertex Pharmaceuticals Announces Webcast of its Presentation at the UBS 2008 Global Life Sciences Conference
Vertex Pharmaceuticals Announces Pricing of its Public Offering of Common Stock
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock - Sep 17 2008 5:21PM
Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences - Sep 4 2008 4:27PM
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Thomas Weisel Partners Healthcare Conference 2008
Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Adams 28th Annual Global Growth Conference
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference
Vertex Pharmaceuticals Highlights Telaprevir Progress and Reports Second Quarter 2008 Results
Vertex Pharmaceuticals Announces the Date of its Second Quarter 2008 Financial Results Conference Call and Webcast
Vertex Pharmaceuticals Announces the Appointment of Freda C. Lewis-Hall, M.D., as Executive Vice President, Medicines Development
Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
Vertex Pharmaceuticals Sells HIV Product Royalty Stream for $160 Million
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 Citi Investment Research Global Healthcare Conference - May 27 2008 12:56AM
Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting - May 27 2008 12:54AM
CORRECTING and REPLACING Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences - Jun 2 2008 2:18AM
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences - Jun 2 2008 2:18AM
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Deutsche Bank 33rd Annual Health Care Conference - Jun 2 2008 2:18AM
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
BellwetherReport.com Initiates Analyst Coverage on PLXS, VRTX, SPAR and WAVE
Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment
Market Alert: UDTT Is Still on the Move!
Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments
Vertex Pharmaceuticals Reviews Clinical Advancements and Reports First Quarter 2008 Financial Results
Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
Law Offices of Brodsky & Smith, LLC Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord\|Adams Hepatitis C Conference
Vertex Pharmaceuticals Announces the Date of its First Quarter 2008 Financial Results Conference Call and Webcast
Stock to Watch: MIHS! April 2, 2008